Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07384130

Oral Probiotics for Halitosis in Healthy Adults

The aim of this study is to evaluate efficacy of a probiotic lozenge containing BLIS M18, BLIS K12 and a prebiotic in healthy adults.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Halitosis Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Blis Technologies Ltd

Dunedin, Otago, 9012, New Zealand

About this study

This is a double-blind, randomized controlled colonization pilot study with no crossover to evaluate the efficacy of probiotic lozenges on halitosis in healthy adults.

Participants will be randomly assigned to 2 groups consuming probiotic lozenge containing Streptococcus salivarius M18 and K12 and with prebiotic over a 13 day period. Breath scores will be measured at predetermined time points pre and post intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants should be otherwise healthy,
  • practice good oral hygiene,
  • 18 - 70 years of age

Exclusion criteria

  • on antibiotic therapy,
  • immunocompromised (have a weakened immune system)
  • history of autoimmune disease,
  • allergy or sensitivity to dairy,
  • have an active periodontal disease, any known allergy or sensitivity to components of the test product or cysteine solution.

Treatment and study plan

In this study, a probiotic lozenge formulation containing S. salivarius K12, M18 and prebiotic will be evaluated for its potential to improve bad breath

Dietary Supplement

In this study, a probiotic-free lozenge formulation containing S. salivarius K12, M18 and prebiotic will be evaluated for its potential to improve bad breath as a comparator.

Placebo

Other

Probiotic free placebo lozenge

Primary outcomes

  1. Measurement of Volatile Sulphur Compounds in ppb between the active and placebo groups

    Time frame: 13 days

    Study will determine the change in Volatile Sulphur Compounds (VSCs) as measured in ppb, following application of probiotic lozenges containing Streptococcus salivarius K12, Streptococcus salivarius M18 and prebiotic compared with a placebo lozenge. Statistical analysis (e.g. Students t-test) will be carried out to compare the participants data from baseline to post cysteine mouthrinse before the lozenge application and 13 days after once a day lozenge application with the level of significance of p≤0.05 across the probiotic and placebo lozenge. Appropriate statistical analysis software (e.g. Microsoft Excel) will be used to analyse the data

Study contacts

Contact information is provided by the study sponsor or research team.

John D Hale, PhD

CONTACT

[email protected]

+6434740988

Rohit Jain, PhD

CONTACT

[email protected]

+6434740988

Sponsors and collaborators

Lead sponsor

John Hale

Industry

Registry information

Official study title

Efficacy of Oral Probiotics on Cysteine-Induced Halitosis in Healthy Adult Volunteers.

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 3, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.